Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 20 de 27
Filtrar
1.
Pharmacol Res ; 171: 105778, 2021 09.
Artículo en Inglés | MEDLINE | ID: mdl-34298110

RESUMEN

The plant Sophora flavescens Ait. has been used in the clinical management of colorectal cancer (CRC). Its constituent compounds, notably the alkaloids matrine, oxymatrine, and sophoridine, have received considerable research attention in experimental models of CRC in vivo and in vitro. This review found that extracts of S. flavescens and/or its constituent compounds have been reported to inhibit CRC cell proliferation by inducing cell-cycle arrest at the G1 phase, inducing apoptosis via the intrinsic pathway, interfering in cancer metabolism, inhibiting metastasis and angiogenesis, regulating senescence and telomeres, regulating the tumour microenvironment and down-regulating cancer-related inflammation. In addition, matrine and oxymatrine reversed multi-drug resistance and enhanced the effects of chemotherapies. These anti-cancer effects were associated with regulation of several cellular signalling pathways including: MAPK/ERK, PI3K/AKT/mTOR, p38MAPK, NF-κB, Hippo/LATS2, TGF-ß/Smad, JAK/STAT3, RhoA/ROC, and Wnt/ ß-catenin pathways. These multiple actions in CRC suggest the alkaloids of S. flavescens may be therapeutic candidates for CRC management. Nevertheless, there remains considerable scope for future research into its flavonoid constituents, the effects of combinations of compounds, and the interaction between these compounds and anti-cancer drugs. In addition, more research is needed to investigate likely drug ligand-receptor interactions for each of the bioactive compounds.


Asunto(s)
Alcaloides/uso terapéutico , Antineoplásicos Fitogénicos/uso terapéutico , Neoplasias Colorrectales/tratamiento farmacológico , Quinolizinas/uso terapéutico , Sophora , Animales , Humanos , Fitoterapia , Matrinas
2.
Immunology ; 148(4): 363-76, 2016 08.
Artículo en Inglés | MEDLINE | ID: mdl-27135915

RESUMEN

Dengue virus (DENV) infection is an emerging public health hazard threatening inhabitants of the tropics and sub-tropics. Dendritic cells (DCs) are one of the major targets of DENV and the initiators of the innate immune response against the virus. However, current in vitro research on the DENV-DC interaction is hampered by the low availability of ex vivo DCs and donor variation. In the current study, we attempted to develop a novel in vitro DC model using immature DCs derived from the myeloid leukaemia cell line MUTZ-3 (IMDCs) to investigate the DENV-DC interaction. The IMDCs morphologically and phenotypically resembled human immature monocyte-derived dendritic cells (IMMoDCs). However, the permissiveness of IMDCs to DENV2 was lower than that of IMMoDCs. RT-PCR arrays showed that a group of type I interferon (IFN) -inducible genes, especially IFIT1, IFITM1, and IFI27, were significantly up-regulated in IMMoDCs but not in IMDCs after DENV2 infection. Further investigation revealed that IFIT genes were spontaneously expressed at both transcriptional and protein levels in the naive IMDCs but not in the naive IMMoDCs. It is possible that the poor permissiveness of IMDCs to DENV2 was a result of the high basal levels of IFIT proteins. We conclude that the IMDC model, although less permissive to DENV2, is a useful platform for studying the suppression mechanism of DENV2 and we expand the knowledge of cellular factors that modulate DENV2 infection in the human body.


Asunto(s)
Antígenos de Diferenciación/metabolismo , Proteínas Portadoras/metabolismo , Células Dendríticas/virología , Virus del Dengue/inmunología , Dengue/inmunología , Proteínas de la Membrana/metabolismo , Monocitos/virología , Proteínas Adaptadoras Transductoras de Señales , Antígenos de Diferenciación/genética , Proteínas Portadoras/genética , Diferenciación Celular , Línea Celular , Células Dendríticas/fisiología , Dengue/genética , Humanos , Inmunidad Innata/genética , Interferón Tipo I/metabolismo , Proteínas de la Membrana/genética , Monocitos/fisiología , Proteínas de Unión al ARN , Transcriptoma , Regulación hacia Arriba
3.
Microb Ecol ; 64(2): 431-49, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-22430508

RESUMEN

The bioactive compounds of medicinal plants are products of the plant itself or of endophytes living inside the plant. Endophytes isolated from eight different anticancer plants collected in Yunnan, China, were characterized by diverse 16S and 18S rRNA gene phylogenies. A functional gene-based molecular screening strategy was used to target nonribosomal peptide synthetase (NRPS) and type I polyketide synthase (PKS) genes in endophytes. Bioinformatic analysis of these biosynthetic pathways facilitated inference of the potential bioactivity of endophyte natural products, suggesting that the isolated endophytes are capable of producing a plethora of secondary metabolites. All of the endophyte culture broth extracts demonstrated antiproliferative effects in at least one test assay, either cytotoxic, antibacterial or antifungal. From the perspective of natural product discovery, this study confirms the potential for endophytes from medicinal plants to produce anticancer, antibacterial and antifungal compounds. In addition, PKS and NRPS gene screening is a valuable method for screening isolates of biosynthetic potential.


Asunto(s)
Bacterias/crecimiento & desarrollo , Endófitos/crecimiento & desarrollo , Hongos/crecimiento & desarrollo , Péptido Sintasas/genética , Plantas Medicinales/microbiología , Sintasas Poliquetidas/genética , Antibacterianos/metabolismo , Antifúngicos/metabolismo , Bacterias/clasificación , Bacterias/genética , Bacterias/aislamiento & purificación , China , Medios de Cultivo , Endófitos/enzimología , Endófitos/genética , Endófitos/aislamiento & purificación , Hongos/clasificación , Hongos/genética , Hongos/aislamiento & purificación , Genes de ARNr , Datos de Secuencia Molecular , Filogenia , ARN Ribosómico 16S/genética , ARN Ribosómico 18S/genética , Análisis de Secuencia de ADN
4.
BMJ Open ; 12(4): e057980, 2022 04 01.
Artículo en Inglés | MEDLINE | ID: mdl-35365537

RESUMEN

INTRODUCTION: Qigong and tai chi (QTC) have been adopted by many patients with cancer as a complementary treatment with their conventional mainstream cancer management. Findings from current systematic reviews are inconsistent. Some research indicated that either qigong or tai chi interventions could enhance quality of life (QoL), and improve cancer-related symptoms such as fatigue, sleep disturbance and anxiety; while others argued that there was a lack of efficacy of QTC on QoL improvement. This umbrella review will analyse and synthesise the findings from published systematic reviews and meta-analyses regarding the effectiveness of QTC in the QoL of patients with cancer. Twenty-five databases will be searched from their respective inception to December 2021. METHODS AND ANALYSIS: We will conduct a search in 21 English and 4 Chinese databases to identify qualified systematic reviews and meta-analyses. Two reviewers will independently screen all the titles and abstracts, and determine whether the article meets the inclusion criteria. After the identified systematic reviews and/or meta-analyses are confirmed, important information from each article will be extracted to the characteristics table by two reviewers independently. Two reviewers will independently analyse the quality of the selected reviews based on the Assessment of Multiple Systematic Reviews guideline. Findings from the systematic reviews and/or meta-analyses will be summarised and reported. ETHICS AND DISSEMINATION: This review does not require ethics approval as the study is based on the published articles. The results drawn from the present review will be submitted to peer-reviewed journals for publication or presented at conferences. PROSPERO REGISTRATION NUMBER: CRD42021253216.


Asunto(s)
Neoplasias , Qigong , Taichi Chuan , Trastornos de Ansiedad , Humanos , Neoplasias/terapia , Calidad de Vida , Literatura de Revisión como Asunto
5.
J Tradit Complement Med ; 12(5): 437-446, 2022 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-36081815

RESUMEN

Rheumatoid Arthritis (RA) remains a major global public health challenge. Disease-modifying anti-rheumatic drugs (DMARDs) are standard therapeutic drugs for RA. Conventional DMARDs (c-DMARDs) are a subgroup of approved synthetic DMARDs. The c-DMARDs experienced lesser response with longer disease duration or drug exposure, and unwanted adverse events (AEs). The combination treatments (CTs) of c-DMARDs and Chinese Herbal Medicines (CHMs) were often used in RA clinical trials for increasing the therapeutic effectiveness and reducing the AEs. This systematic review aimed to evaluate the efficacy and safety of the CTs for RA. Databases were searched from inception to October 2020 for identification of randomized controlled trials (RCTs) that investigated the CTs in the management of RA. Twenty-three RCTs with 2,441 participants were included. The assessments and analyses found CTs improved American College of Rheumatology (ACR) 20 (RR: 1.33, 95% CI [1.21, 1.45], 10 studies, n=1,075) and alleviated AEs (RR: -0.40, 95% CI [-0.30, -0.53], 19 studies, n=2,011) in comparison with c-DMARDs. The CTs also significantly improved RA symptoms and patient-reported outcomes; reduced disease activity score (DAS) 28, serum acute-phase reactants and RA biomarkers. The five most commonly used herbs in included studies were Angelicae Sinensis Radix, Paeoniae Radix Alba, Cinnamomi Ramulus, Glycyrrhizae Radix et Rhizoma, and Clematidis Radix et Rhizoma. Pharmacological studies indicated these CHMs could contribute to the outcomes. The integrated CHMs potentially increased the overall effectiveness of c-DMARDs and alleviated AEs in management of RA. Large sample and rigorously designed RCTs are required for future studies.

6.
Blood Adv ; 3(24): 4298-4311, 2019 12 23.
Artículo en Inglés | MEDLINE | ID: mdl-31869418

RESUMEN

The Bruton's tyrosine kinase (Btk) inhibitor ibrutinib has proven to be efficacious in the treatment of B-cell chronic lymphocytic leukemia (B-CLL) and related diseases. However, a major adverse side effect of ibrutinib is bleeding, including major hemorrhages. The bleeding associated with ibrutinib use is thought to be due to a combination of on-target irreversible Btk inhibition, as well as off-target inhibition of other kinases, including EGFR, ITK, JAK3, and Tec kinase. In this study, we investigated the effects of ibrutinib vs zanubrutinib (a more selective Btk inhibitor) on platelet activation, glycoprotein expression, and thrombus formation. Ibrutinib, but not zanubrutinib, induced a time- and dose-dependent shedding of GPIb-IX complex and integrin αIIbß3, but not of GPVI and GPV, from the platelet surface. The shedding of GPIbα and GPIX was blocked by GM6001 and TAPI-2, an ADAM17 inhibitor but not ADAM10 inhibitor. Ibrutinib but not zanubrutinib treatment of human platelets increased ADAM17 activation. Pretreatment of C57BL/6 mice with ibrutinib (10 mg/kg), but not zanubrutinib (10 mg/kg), inhibited ex vivo and in vivo thrombus growth over time. Platelets from ibrutinib-treated patients with CLL showed reduced GPIb-IX complex and integrin αIIbß3 surface expression and reduced ex vivo thrombus formation under arterial flow, which was not observed in zanubrutinib-treated patients. In mice, ibrutinib, but not zanubrutinib, led to increased soluble GPIbα and soluble αIIb levels in plasma. These data demonstrate that ibrutinib induces shedding of GPIbα and GPIX by an ADAM17-dependent mechanism and integrin αIIbß3 by an unknown sheddase, and this process occurs in vivo to regulate thrombus formation.


Asunto(s)
Plaquetas/efectos de los fármacos , Plaquetas/metabolismo , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/metabolismo , Complejo GPIb-IX de Glicoproteína Plaquetaria/metabolismo , Inhibidores de Proteínas Quinasas/farmacología , Pirazoles/farmacología , Pirimidinas/farmacología , Adenina/análogos & derivados , Animales , Biomarcadores , Colágeno Tipo I/metabolismo , Exocitosis , Humanos , Ratones , Piperidinas/farmacología , Activación Plaquetaria/efectos de los fármacos , Factor de von Willebrand/metabolismo
7.
Artículo en Inglés | MEDLINE | ID: mdl-31565062

RESUMEN

BACKGROUND AND AIM: The progression of liver fibrosis in chronic hepatitis B (CHB) patients is currently insufficiently controlled worldwide. The Yi Guan Jian decoction (YGJD) has been widely used in the treatment of liver fibrosis in CHB cases. Although animal studies have reported the antifibrotic effects of the decoction, the active ingredients of the YGJD remain unknown. This study aimed at identifying the potential active ingredients and exploring the mechanisms of action (MOA) of the decoction when treating CHB patients with fibrosis. METHODS: Using data mining techniques and a structural clustering analysis, the potential active ingredients were determined. A network analysis of the differentially expressed genes was conducted to identify the potential targets. Selected compounds were docked to the potential targets for the compound-target interaction simulation. In vitro validation, including a cell proliferation assay and Western blot analysis, was conducted to evaluate the prediction results. RESULTS: In the microarray data, 224 differentially expressed genes related to liver fibrosis were considered to be potential targets. Thirty active ingredients of the YGJD and 15 main targets and relevant pathways were identified. Among them, two active ingredients, methylophiopogonone A and 8-geranyloxypsoralen, were validated as exhibiting antifibrotic effects on hepatic stellate cells. CONCLUSIONS: We identified the potential active ingredients of the YGJD and proposed the possible explanation for the MOA in the treatment of CHB patients with liver fibrosis. Moreover, this study provides a methodological reference for the systematic investigation of the bioactive compounds and related MOA of a traditional Chinese medicine formula in a clinical context.

8.
Assay Drug Dev Technol ; 6(5): 711-21, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-19035851

RESUMEN

There are substances that kill cancer cells, but induce T cell proliferation, like thalidomide. To find more of these, a new anticancer drug screening strategy is vital. In this study we report the development of a differential cytotoxicity screening or evaluation platform using the CellTiter-Glo (Promega, Annandale, NSW, Australia) luminescent cell viability assay (ATP assay) and also the CellTiter 96 AQueous (Promega) one solution cell proliferation assay [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay]. The results suggested the platform consisting of the combination of the ATP assay be used for quantifying peripheral blood mononuclear cells, while the more economic MTS colorimetric assay is well suited to be used detecting cell viability of cancer cells. In addition, we found paclitaxel (Taxol, MP Biomedicals Australasia Pty Ltd., Seven Hills, NSW, Australia) to be a useful control for this routine screening methodology. Taxol exhibits the desirable in vitro feature of differential cytotoxicity that spares the immunological cells, when used at a concentration that will kill the majority of the cancer cell population.


Asunto(s)
Antineoplásicos/farmacología , Ensayos de Selección de Medicamentos Antitumorales/instrumentación , Adenosina Trifosfato/metabolismo , Antineoplásicos Fitogénicos/farmacología , Línea Celular Tumoral , Separación Celular , Supervivencia Celular/efectos de los fármacos , Colorimetría , Colorantes , Ensayos de Selección de Medicamentos Antitumorales/métodos , Humanos , Indicadores y Reactivos , Monocitos/efectos de los fármacos , Mieloma Múltiple/tratamiento farmacológico , Mieloma Múltiple/patología , Paclitaxel/farmacología , Própolis/farmacología , Reproducibilidad de los Resultados , Sales de Tetrazolio , Tiazoles , Azul de Tripano
9.
J Altern Complement Med ; 24(2): 115-124, 2018 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-29068694

RESUMEN

BACKGROUND: The majority of studies of integrative treatment for colorectal cancer (CRC) have been published in Chinese journals. These studies indicate potential benefits, but concerns have been raised over the quality of trials published in Chinese journals. The CONSORT statement provides a guide for study reporting that has been endorsed by more than 400 international journals. Previous studies have used the CONSORT checklist to assess the quality of randomized controlled trials (RCTs). OBJECTIVES: This study focused on RCTs of integrative and traditional medicine for CRC published in Chinese journals and assessed: (1) the overall quality of reporting with a focus on methodological aspects; (2) change over time; and (3) the influence of study funding, level of institution conducting the trial, rank of the journal, and the length of the article. DESIGN: Searches of seven databases identified RCTs. Quality was assessed using CONSORT 2010 with adaptations to facilitate scoring. Additional codes were added for publication year, hospital rank, report length, and status of the journal. Scores of each checklist item, total scores, and scores for eight items associated with RCT methodology were calculated. RESULTS: Eighty-one studies were included in the main analyses. The RCT methodology subgroup scores were significantly higher in studies: with public funding, conducted by authors from university hospitals, published in higher ranked journals, and in longer articles. CONCLUSIONS: Few Chinese journals mention CONSORT in their author guidelines. In these RCTs on CRC better reporting of RCT methodology was associated with ranking of the journal as "core," public funding of the RCT, and first or correspondent author from a university hospital but the quality of reporting had not significantly improved in 15 years. As the volume of scientific information produced in China grows, it is imperative that there is growth in the quality of this information.


Asunto(s)
Neoplasias Colorrectales/terapia , Medicina Integrativa/normas , Publicaciones/normas , Ensayos Clínicos Controlados Aleatorios como Asunto/normas , Lista de Verificación , Humanos
10.
Immunobiology ; 223(4-5): 356-364, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29113699

RESUMEN

Caspase-4 physically interacts with caspase-1 and is believed to be a proinflammatory caspase that can induce the inflammatory form of programmed cell death (pyroptosis) and the release of mature interleukin (IL)-1ß. However, the function of caspase-4 in dengue virus infection is not yet fully understood. We examined the function of caspase-4 in IL-1ß production and pyroptosis during dengue virus serotype-2 (DENV-2) infection in human macrophages. In this study, DENV-2 infection increased IL-1ß protein level with activated caspase-4 activity. Using primary macrophages, we observed that caspase-4 induces activation of caspase-1 and secretion of IL-1ß in response to DENV-2 infection, without the need for secondary signals to stimulate the assembly of the inflammasome. These findings indicate that the regulation of caspase-1 activity by capsase-4 could represent a unique mechanism. Our data suggest that caspase-4 is upstream of caspase-1 in the pathway that regulates pyroptosis and IL-1ß synthesis in macrophages during DENV-2 infection.


Asunto(s)
Caspasa 1/metabolismo , Caspasas Iniciadoras/metabolismo , Virus del Dengue/inmunología , Dengue/inmunología , Macrófagos/inmunología , Células Cultivadas , Humanos , Inflamasomas/metabolismo , Interleucina-1beta/metabolismo , Macrófagos/virología , Cultivo Primario de Células , Unión Proteica , Piroptosis
11.
Chin Med ; 13: 64, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30598693

RESUMEN

BACKGROUND: The incidence and mortality of cancer metastasis is high worldwide. Despite of the chemotherapeutic agents, many cancer patients still take traditional Chinese herbal prescriptions as adjuvant treatments. However, most of these herbal formulae/products lack of evidence-based efficacy. Based on our previous investigations on anti-tumor, anti-angiogenic, anti-metastatic, bone protective and immunomodulating activities of various Chinese herbal medicines, four constituent herbs, namely Andrographis paniculata, Acanthopanax senticosus, Camellia sinensis, and Hedyotis diffusa were eventually selected to form an innovative herbal formula. METHODS: The anti-tumor efficacies of the formula were evaluated in metastatic breast cancer mice model. The bone protective and immunomodulatory effects were also assessed after formula treatment. RESULTS: Our results showed that the breast tumor weight as well as lung and liver metastasis in mice could be reduced after herbal formula treatment for 4 weeks. The breast tumor-induced osteolysis in mice was restored by herbal formula treatment, in which the bone volume in treated mice tibia was comparable to that in the non-tumor bearing normal mice. The IL-12 level was augmented and the survival of mice with metastatic breast tumors was prolonged after treatment. Furthermore, combination of herbal formula with chemotherapeutic agent doxorubicin resulted in better anti-tumor efficacy and increased life span in tumor-bearing mice, when compared with doxorubicin alone treatment. CONCLUSIONS: In summary, our innovative Chinese herbal formula was demonstrated to possess anti-tumor, anti-metastatic and bone-protective activities in metastatic breast tumor-bearing mice. The preclinical data generated in this study would lead to the development of evidence-based supplement as adjuvant therapy for metastatic breast cancer.

12.
Int J Hematol ; 86(5): 429-37, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-18192112

RESUMEN

Our previous studies demonstrated that a low concentration of 2-methoxyestradiol (2ME2) could induce the differentiation of myeloma cell lines and CD138+ primary myeloma cells from myeloma patients and up-regulate the expression of messenger RNA (mRNA) and protein for the gene encoding X-box binding protein 1 (Xbp-1) in myeloma cell lines. In the present study, we used phosphorothioated antisense oligodeoxynucleotides (ASODN) to investigate the roles and interactions of transcription factors Xbp-1, B-lymphocyte induced maturation protein 1 (Blimp-1), and PAX-5-encoded B-cell-specific activator protein (BSAP), which are thought to be involved in the regulation of B-lymphocytic or plasmacytic differentiation. Blimp-1 ASODN and Xbp-1 ASODN clearly inhibited myeloma cell differentiation and significantly partially inhibited the differentiation effects induced by 2ME2 at low concentration, whereas PAX-5 ASODN clearly induced myeloma cell differentiation and significantly enhanced 2ME2-induced differentiation effects. Moreover, after incubation with Blimp-1 ASODN, the level of Xbp-1 mRNA clearly declined, whereas the level of PAX-5 mRNA significantly increased in myeloma cells. These results demonstrate that transcription factors Xbp-1, Blimp-1, and PAX-5-encoded BSAP play important roles in the regulation of plasmacytic differentiation and exert their effects on differentiation induced by low 2ME2 concentrations. Our primary study provided the rationale for a promising strategy-the future application of transcription-factor ASODN for clinical patients.


Asunto(s)
Diferenciación Celular/efectos de los fármacos , Proteínas de Unión al ADN/metabolismo , Estradiol/análogos & derivados , Mieloma Múltiple/metabolismo , Proteínas Nucleares/metabolismo , Factor de Transcripción PAX5/metabolismo , Células Plasmáticas/metabolismo , Proteínas Represoras/metabolismo , Factores de Transcripción/metabolismo , Moduladores de Tubulina/farmacología , 2-Metoxiestradiol , Diferenciación Celular/genética , Línea Celular Tumoral , Proteínas de Unión al ADN/antagonistas & inhibidores , Proteínas de Unión al ADN/genética , Relación Dosis-Respuesta a Droga , Estradiol/farmacología , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Humanos , Mieloma Múltiple/tratamiento farmacológico , Mieloma Múltiple/genética , Mieloma Múltiple/patología , Proteínas Nucleares/antagonistas & inhibidores , Proteínas Nucleares/genética , Oligodesoxirribonucleótidos Antisentido/genética , Oligodesoxirribonucleótidos Antisentido/farmacología , Oligodesoxirribonucleótidos Antisentido/uso terapéutico , Factor de Transcripción PAX5/antagonistas & inhibidores , Factor de Transcripción PAX5/genética , Células Plasmáticas/patología , Factor 1 de Unión al Dominio 1 de Regulación Positiva , Factores de Transcripción del Factor Regulador X , Proteínas Represoras/antagonistas & inhibidores , Proteínas Represoras/genética , Sindecano-1/genética , Sindecano-1/metabolismo , Factores de Transcripción/antagonistas & inhibidores , Factores de Transcripción/genética , Regulación hacia Arriba/efectos de los fármacos , Proteína 1 de Unión a la X-Box
13.
Biomed Res Int ; 2017: 3923865, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28337449

RESUMEN

The current use of a single chemical component as the representative quality control marker of herbal food supplement is inadequate. In this CD80-Quantitative-Pattern-Activity-Relationship (QPAR) study, we built a bioactivity predictive model that can be applicable for complex mixtures. Through integrating the chemical fingerprinting profiles of the immunomodulating herb Radix Astragali (RA) extracts, and their related biological data of immunological marker CD80 expression on dendritic cells, a chemometric model using the Elastic Net Partial Least Square (EN-PLS) algorithm was established. The EN-PLS algorithm increased the biological predictive capability with lower value of RMSEP (11.66) and higher values of Rp2 (0.55) when compared to the standard PLS model. This CD80-QPAR platform provides a useful predictive model for unknown RA extract's bioactivities using the chemical fingerprint inputs. Furthermore, this bioactivity prediction platform facilitates identification of key bioactivity-related chemical components within complex mixtures for future drug discovery and understanding of the batch-to-batch consistency for quality clinical trials.


Asunto(s)
Antígeno B7-1/biosíntesis , Medicamentos Herbarios Chinos/administración & dosificación , Factores Inmunológicos/administración & dosificación , Extractos Vegetales/administración & dosificación , Astragalus propinquus , Antígeno B7-1/química , Línea Celular , Células Dendríticas/efectos de los fármacos , Descubrimiento de Drogas , Medicamentos Herbarios Chinos/química , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Factores Inmunológicos/química , Extractos Vegetales/química , Relación Estructura-Actividad Cuantitativa
14.
Crit Rev Oncol Hematol ; 105: 18-34, 2016 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-27497028

RESUMEN

This review assessed the effects on chemotherapy induced neutropenia (CIN) of combining oxaliplatin regimens with traditional plant-based medicines (TMs) in the management of colorectal cancer (CRC). 32 RCTs (2224 participants) were included. Meta-analysis showed reduced incidence of grade 3/4 CIN (RR 0.45[0.31, 0.65], I(2)=0%). No studies reported serious adverse events or reduction in tumour response rates associated with concurrent use of oxaliplatin and TM. Due to small sample sizes and risk of bias, these results should be interpreted with caution. Analyses of sub-groups of studies that used similar TM interventions assessed the relative contributions of individual plant-based ingredients to the results. Astragalus, Codonopsis, Atractylodes, Poria and Coix, in various combinations were consistently associated with reduced CIN incidence when administered orally. Experimental studies of these plants have reported reduced myelosuppression and/or enhanced immune response. Further studies of these plants may lead to the development of interventions to supplement conventional CIN treatment.


Asunto(s)
Neoplasias Colorrectales/tratamiento farmacológico , Neutropenia/inducido químicamente , Compuestos Organoplatinos/efectos adversos , Animales , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Humanos , Incidencia , Neutropenia/epidemiología , Compuestos Organoplatinos/uso terapéutico , Oxaliplatino
15.
PLoS One ; 11(1): e0146881, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26799072

RESUMEN

Polysaccharopeptide (PSP), from Coriolus versicolor, has been used widely as an adjuvant to chemotherapy with demonstrated anti-tumor and broad immunomodulating effects. While PSP's mechanism of action still remains unknown, its enhanced immunomodulatory potential with acacia gum is of great interest. Acacia gum, which also contains polysaccharides and glycoproteins, has been demonstrated to be immunopotentiating. To elucidate whether PSP directly activates T-cell-dependent B-cell responses in vivo, we used a well-established hapten carrier system (Nitrophenyl-chicken gamma globulin (NP-CGG)). 6-week C57BL/6 male mice were immunised with 50 µg of NP25-CGG alum precipitate intraperitoneally. Mice were gavaged daily with 50 mg/kg PSP in a vehicle containing acacia gum and sacrificed at days 0, 4, 7, 10, 14 and 21. ELISA was used to measure the total and relative hapten-specific anti-NP IgA, IgM and IgG titre levels compared to the controls. It was found that PSP, combined with acacia gum, significantly increased total IgG titre levels at day 4 (P< 0.05), decreased IgM titre levels at days 4 and 21 (P< 0.05) with no alterations observed in the IgA or IgE titre levels at any of the time points measured. Our results suggest that while PSP combined with acacia gum appears to exert weak immunological effects through specific T-cell dependent B-cell responses, they are likely to be broad and non-specific which supports the current literature on PSP. We report for the first time the application of a well-established hapten-carrier system that can be used to characterise and delineate specific T-cell dependent B-cell responses of potential immunomodulatory glycoprotein-based herbal medicines combinations in vivo.


Asunto(s)
Anticuerpos/sangre , Linfocitos B/inmunología , Goma Arábiga/farmacología , Proteoglicanos/inmunología , Linfocitos T/inmunología , gamma-Globinas/inmunología , Adyuvantes Inmunológicos/farmacología , Animales , Anticuerpos/inmunología , Haptenos/inmunología , Inmunización , Inmunoglobulina G/sangre , Inmunoglobulina G/inmunología , Inmunoglobulina M/sangre , Inmunoglobulina M/inmunología , Inmunoterapia/métodos , Activación de Linfocitos/inmunología , Masculino , Ratones , Ratones Endogámicos C57BL , Neoplasias/terapia , Nitrofenoles/inmunología , Fenilacetatos/inmunología , Proteoglicanos/farmacología , Trametes/inmunología
16.
Methods Mol Biol ; 271: 111-25, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15146116

RESUMEN

This chapter describes the analysis of long- and short-lived plasma cells on tissue sections. Mice are immunized with 4-hydroxy-3-nitrophenyl acetyl (NP) coupled to a T-cell-dependent carrier. Antigen-specific germinal center cells and extrafollicular plasma cells are identified by immunohistology on tissue sections. Plasma cells labeled with 5-bromo-2'-deoxyuridine (BrdU) pulses given during different phases of B-cell response are identified on spleen sections. To identify mutated cells originating from cells in germinal centers, antigen-specific cells from spleen sections are isolated by microdissection. From these NP-specific recombined VDJ genes are amplified with family-specific primers by polymerase chain reaction (PCR) for deoxyribonucleic acid (DNA) sequencing. The methods described can be used to characterize origins and life-span of plasma cells in vivo.


Asunto(s)
Linfocitos B/citología , Diferenciación Celular/inmunología , Centro Germinal/citología , Células Plasmáticas/citología , Bazo/inmunología , Animales , Linfocitos B/inmunología , Bromodesoxiuridina/química , Pollos/inmunología , Centro Germinal/inmunología , Inmunización , Ratones , Microdisección , Mutación , Nitrofenoles/inmunología , Fenilacetatos , Células Plasmáticas/inmunología , Reacción en Cadena de la Polimerasa , Receptores de Antígenos de Linfocitos B/inmunología , Receptores de Antígenos de Linfocitos B/metabolismo , Ovinos/inmunología , Linfocitos T Colaboradores-Inductores/citología , Linfocitos T Colaboradores-Inductores/inmunología
17.
Clin Rev Allergy Immunol ; 44(3): 262-73, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22707327

RESUMEN

Propolis, a waxy substance produced by the honeybee, has been adopted as a form of folk medicine since ancient times. It has a wide spectrum of alleged applications including potential anti-infection and anticancer effects. Many of the therapeutic effects can be attributed to its immunomodulatory functions. The composition of propolis can vary according to the geographic locations from where the bees obtained the ingredients. Two main immunopotent chemicals have been identified as caffeic acid phenethyl ester (CAPE) and artepillin C. Propolis, CAPE, and artepillin C have been shown to exert summative immunosuppressive function on T lymphocyte subsets but paradoxically activate macrophage function. On the other hand, they also have potential antitumor properties by different postulated mechanisms such as suppressing cancer cells proliferation via its anti-inflammatory effects; decreasing the cancer stem cell populations; blocking specific oncogene signaling pathways; exerting antiangiogenic effects; and modulating the tumor microenvironment. The good bioavailability by the oral route and good historical safety profile makes propolis an ideal adjuvant agent for future immunomodulatory or anticancer regimens. However, standardized quality controls and good design clinical trials are essential before either propolis or its active ingredients can be adopted routinely in our future therapeutic armamentarium.


Asunto(s)
Antineoplásicos Fitogénicos/farmacología , Factores Inmunológicos/farmacología , Própolis/farmacología , Inhibidores de la Angiogénesis/farmacología , Animales , Antineoplásicos Fitogénicos/química , Antineoplásicos Fitogénicos/uso terapéutico , Ácidos Cafeicos/farmacología , Línea Celular Tumoral , Humanos , Factores Inmunológicos/química , Factores Inmunológicos/uso terapéutico , Neoplasias/tratamiento farmacológico , Neoplasias/inmunología , Neoplasias/metabolismo , Células Madre Neoplásicas/efectos de los fármacos , Proteínas Oncogénicas/metabolismo , Alcohol Feniletílico/análogos & derivados , Alcohol Feniletílico/farmacología , Fenilpropionatos/farmacología , Própolis/química , Própolis/uso terapéutico , Transducción de Señal/efectos de los fármacos , Subgrupos de Linfocitos T/efectos de los fármacos , Microambiente Tumoral/efectos de los fármacos
18.
Artículo en Inglés | MEDLINE | ID: mdl-23818930

RESUMEN

This paper is a systematic review of evidence-based studies of the effectiveness of Chinese herbal medicine (CHM) in the treatment of liver cancer. After a detailed analysis of the literature, five animal studies and four human clinical trials met the criteria for inclusion. Analysis revealed that results of the clinical trials, whilst encouraging, need to be interpreted with caution as problems with study designs may lead to apparent benefits being attributable to various forms of bias. However, as each of the CHM agents used in these studies appeared to be potentially beneficial, further well-designed and controlled randomized clinical trials are warranted. The second part of this review focused on the lessons learned from the relationships between Traditional Chinese Medicine (TCM) theory, TCM Syndrome Differentiation, and modern scientific understanding of mechanisms of action of CHM agents. The understanding of TCM Syndrome Differentiation may allow identification of different patterns of disharmony and may provide important guidance to the prescription of CHM. Furthermore, quality control using both biological and chemical fingerprinting of CHM is important to ensure batch-to-batch consistency to deliver sustained therapeutic benefit. Also, careful assessment of herb-drug interactions is paramount for safety and integrative use of western chemotherapeutic and CHM agents.

19.
Comput Math Methods Med ; 2013: 971272, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24288577

RESUMEN

Research on core and effective formulae (CEF) does not only summarize traditional Chinese medicine (TCM) treatment experience, it also helps to reveal the underlying knowledge in the formulation of a TCM prescription. In this paper, CEF discovery from tumor clinical data is discussed. The concepts of confidence, support, and effectiveness of the CEF are defined. Genetic algorithm (GA) is applied to find the CEF from a lung cancer dataset with 595 records from 161 patients. The results had 9 CEF with positive fitness values with 15 distinct herbs. The CEF have all had relative high average confidence and support. A herb-herb network was constructed and it shows that all the herbs in CEF are core herbs. The dataset was divided into CEF group and non-CEF group. The effective proportions of former group are significantly greater than those of latter group. A Synergy index (SI) was defined to evaluate the interaction between two herbs. There were 4 pairs of herbs with high SI values to indicate the synergy between the herbs. All the results agreed with the TCM theory, which demonstrates the feasibility of our approach.


Asunto(s)
Algoritmos , Medicamentos Herbarios Chinos/uso terapéutico , Medicina Tradicional China , Antineoplásicos Fitogénicos/uso terapéutico , Bases de Datos Factuales , Bases de Datos Farmacéuticas , Humanos , Bases del Conocimiento , Neoplasias Pulmonares/tratamiento farmacológico , Fitoterapia
20.
Food Chem ; 138(4): 2201-9, 2013 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-23497877

RESUMEN

Polysaccharopeptide (PSP), from Coriolus versicolor, has been used as an adjuvant to chemotherapy, and has demonstrated anti-tumor and immunomodulating effects. However its mechanism remains unknown. To elucidate how PSP affects immune populations, we compared PSP treatments both with and without prior incubation in phytohaemagglutinin (PHA) - a process commonly used in immune population experimentation. We first standardised a capillary electrophoresis fingerprinting technique for PSP identification and characterisation. We then established the proliferative capability of PSP on various immune populations in peripheral blood mononuclear cells, using flow cytometry, without prior PHA treatment. It was found that PSP significantly increased the number of monocytes (CD14(+)/CD16(-)) compared to controls without PHA. This increase in monocytes was confirmed using another antibody panel of CD14 and MHCII. In contrast, proliferations of T-cells, NK, and B-cells were not significantly changed by PSP. Thus, stimulating monocyte/macrophage function with PSP could be an effective therapeutic intervention in targeting tumors.


Asunto(s)
Factores Inmunológicos/farmacología , Leucocitos Mononucleares/efectos de los fármacos , Neoplasias/terapia , Proteoglicanos/farmacología , Trametes/química , Proliferación Celular/efectos de los fármacos , Células Cultivadas , Humanos , Factores Inmunológicos/química , Leucocitos Mononucleares/citología , Leucocitos Mononucleares/inmunología , Neoplasias/inmunología , Neoplasias/fisiopatología , Fitohemaglutininas/farmacología , Proteoglicanos/química , Proteoglicanos/inmunología
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda